104 related articles for article (PubMed ID: 30779044)
1. Lymphoma and Leukemia Cell Vulnerabilities and Resistance Identified by Compound Library Screens.
Tomska K; Scheinost S; Zenz T
Methods Mol Biol; 2019; 1956():351-362. PubMed ID: 30779044
[TBL] [Abstract][Full Text] [Related]
2. Drug sensitivity assays in leukaemia and lymphoma.
Veerman AJ; Pieters R
Br J Haematol; 1990 Apr; 74(4):381-4. PubMed ID: 2189486
[No Abstract] [Full Text] [Related]
3. Towards a high throughput impedimetric screening of chemosensitivity of cancer cells suspended in hydrogel and cultured in a paper substrate.
Lei KF; Liu TK; Tsang NM
Biosens Bioelectron; 2018 Feb; 100():355-360. PubMed ID: 28946107
[TBL] [Abstract][Full Text] [Related]
4. Large-Scale Gene Expression Profiling Platform for Identification of Context-Dependent Drug Responses in Multicellular Tumor Spheroids.
Senkowski W; Jarvius M; Rubin J; Lengqvist J; Gustafsson MG; Nygren P; Kultima K; Larsson R; Fryknäs M
Cell Chem Biol; 2016 Nov; 23(11):1428-1438. PubMed ID: 27984028
[TBL] [Abstract][Full Text] [Related]
5. Rapid identification and validation of novel targeted approaches for Glioblastoma: A combined ex vivo-in vivo pharmaco-omic model.
Daher A; de Groot J
Exp Neurol; 2018 Jan; 299(Pt B):281-288. PubMed ID: 28923369
[TBL] [Abstract][Full Text] [Related]
6. High-content assays for characterizing the viability and morphology of 3D cancer spheroid cultures.
Sirenko O; Mitlo T; Hesley J; Luke S; Owens W; Cromwell EF
Assay Drug Dev Technol; 2015 Sep; 13(7):402-14. PubMed ID: 26317884
[TBL] [Abstract][Full Text] [Related]
7. Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling.
Sandercock AM; Rust S; Guillard S; Sachsenmeier KF; Holoweckyj N; Hay C; Flynn M; Huang Q; Yan K; Herpers B; Price LS; Soden J; Freeth J; Jermutus L; Hollingsworth R; Minter R
Mol Cancer; 2015 Jul; 14():147. PubMed ID: 26227951
[TBL] [Abstract][Full Text] [Related]
8. Novel drug candidates for blast phase chronic myeloid leukemia from high-throughput drug sensitivity and resistance testing.
Pietarinen PO; Pemovska T; Kontro M; Yadav B; Mpindi JP; Andersson EI; Majumder MM; Kuusanmäki H; Koskenvesa P; Kallioniemi O; Wennerberg K; Heckman CA; Mustjoki S; Porkka K
Blood Cancer J; 2015 May; 5(5):e309. PubMed ID: 25933373
[TBL] [Abstract][Full Text] [Related]
9. High content screening of defined chemical libraries using normal and glioma-derived neural stem cell lines.
Danovi D; Folarin AA; Baranowski B; Pollard SM
Methods Enzymol; 2012; 506():311-29. PubMed ID: 22341231
[TBL] [Abstract][Full Text] [Related]
10. Identification of selective cytotoxic and synthetic lethal drug responses in triple negative breast cancer cells.
Gautam P; Karhinen L; Szwajda A; Jha SK; Yadav B; Aittokallio T; Wennerberg K
Mol Cancer; 2016 May; 15(1):34. PubMed ID: 27165605
[TBL] [Abstract][Full Text] [Related]
11. The relevance of using 3D cell cultures, in addition to 2D monolayer cultures, when evaluating breast cancer drug sensitivity and resistance.
Breslin S; O'Driscoll L
Oncotarget; 2016 Jul; 7(29):45745-45756. PubMed ID: 27304190
[TBL] [Abstract][Full Text] [Related]
12. High-throughput screening of human leukemia xenografts to identify dexamethasone sensitizers.
Toscan CE; Failes T; Arndt GM; Lock RB
J Biomol Screen; 2014 Dec; 19(10):1391-401. PubMed ID: 25104793
[TBL] [Abstract][Full Text] [Related]
13. More than fishing for a cure: The promises and pitfalls of high throughput cancer cell line screens.
Ling A; Gruener RF; Fessler J; Huang RS
Pharmacol Ther; 2018 Nov; 191():178-189. PubMed ID: 29953899
[TBL] [Abstract][Full Text] [Related]
14. Real-time cytotoxicity assays in human whole blood.
Hsiao CW; Lo YT; Liu H; Hsiao SC
J Vis Exp; 2014 Nov; (93):e51941. PubMed ID: 25406660
[TBL] [Abstract][Full Text] [Related]
15. Selective colony area method for heterogeneous patient-derived tumor cell lines in anti-cancer drug screening system.
Cho JH; Kim JS; Kim ST; Hong JY; Park JO; Park YS; Nam DH; Lee DW; Lee J
PLoS One; 2019; 14(4):e0215080. PubMed ID: 30995234
[TBL] [Abstract][Full Text] [Related]
16. A normalized drug response metric improves accuracy and consistency of anticancer drug sensitivity quantification in cell-based screening.
Gupta A; Gautam P; Wennerberg K; Aittokallio T
Commun Biol; 2020 Jan; 3(1):42. PubMed ID: 31974521
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling.
Andersson EI; Pützer S; Yadav B; Dufva O; Khan S; He L; Sellner L; Schrader A; Crispatzu G; Oleś M; Zhang H; Adnan-Awad S; Lagström S; Bellanger D; Mpindi JP; Eldfors S; Pemovska T; Pietarinen P; Lauhio A; Tomska K; Cuesta-Mateos C; Faber E; Koschmieder S; Brümmendorf TH; Kytölä S; Savolainen ER; Siitonen T; Ellonen P; Kallioniemi O; Wennerberg K; Ding W; Stern MH; Huber W; Anders S; Tang J; Aittokallio T; Zenz T; Herling M; Mustjoki S
Leukemia; 2018 Mar; 32(3):774-787. PubMed ID: 28804127
[TBL] [Abstract][Full Text] [Related]
18. Appraisal of the MTT-based assay as a useful tool for predicting drug chemosensitivity in leukemia.
Hayon T; Dvilansky A; Shpilberg O; Nathan I
Leuk Lymphoma; 2003 Nov; 44(11):1957-62. PubMed ID: 14738150
[TBL] [Abstract][Full Text] [Related]
19. Large-Scale Drug Screens Support Precision Medicine.
Gray JW; Mills GB
Cancer Discov; 2015 Nov; 5(11):1130-2. PubMed ID: 26526695
[TBL] [Abstract][Full Text] [Related]
20. Construction and application of a lung cancer stem cell model: antitumor drug screening and molecular mechanism of the inhibitory effects of sanguinarine.
Yang J; Fang Z; Wu J; Yin X; Fang Y; Zhao F; Zhu S; Li Y
Tumour Biol; 2016 Oct; 37(10):13871-13883. PubMed ID: 27485114
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
